SCHEMBL2628649

SCHEMBL2628649

CCOc1ccc(NC(=O)[C@@H]2C[C@H](C)CC[C@H]2C(C)C)cc1

nearest known ligand 0.77

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 4/20 0.77
TP53 P04637 1/20 0.54
POLB P06746 3/20 0.54
TSHR P16473 2/20 0.54
KMT2A Q03164 4/20 0.53
RAB9A P51151 1/20 0.51
LMNA P02545 4/20 0.50
L3MBTL1 Q9Y468 1/20 0.49
MAPT P10636 1/20 0.48
ALDH1A1 P00352 1/20 0.47
MEN1 O00255 2/20 0.47
CYP1A2 P05177 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
TAS1R3 Q7RTX0 1/20 0.46
TAS1R1 Q7RTX1 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2297046 1.00 TRPM8 (0.77) TRPM8TP53POLBTSHRKMT2A
Acoltremon SCHEMBL619824 0.87 TRPM8 (1.00) TRPM8POLBKMT2ARAB9AALDH1A1
Acoltremon SCHEMBL2575067 0.87 TRPM8 (1.00) TRPM8POLBKMT2ARAB9AALDH1A1
Acoltremon SCHEMBL29570327 0.87 TRPM8 (1.00) TRPM8POLBKMT2ARAB9AALDH1A1
Acoltremon SCHEMBL23870506 0.87 TRPM8 (1.00) TRPM8POLBKMT2ARAB9AALDH1A1
Acoltremon SCHEMBL23198293 0.87 TRPM8 (1.00) TRPM8POLBKMT2ARAB9AALDH1A1
Acoltremon SCHEMBL3228667 0.87 TRPM8 (1.00) TRPM8POLBKMT2ARAB9AALDH1A1
Acoltremon SCHEMBL17104729 0.87 TRPM8 (1.00) TRPM8POLBKMT2ARAB9AALDH1A1
Acoltremon SCHEMBL14811473 0.87 TRPM8 (1.00) TRPM8POLBKMT2ARAB9AALDH1A1
Acoltremon SCHEMBL16227989 0.87 TRPM8 (1.00) TRPM8POLBKMT2ARAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130190296-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION DENDREON CORPORATION (US) 2013-07-25 US disclosed
US-8389730-B2 Compositions and methods for the treatment of disease associated with TRP-P8 expression DENDREON CORPORATION (US) 2013-03-05 US disclosed
US-8389730-B2 Compositions and methods for the treatment of disease associated with TRP-P8 expression DENDREON CORPORATION (US) 2013-03-05 US disclosed
US-20120094977-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION DENDREON CORPORATION (US) 2012-04-19 US disclosed
US-20120094977-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION DENDREON CORPORATION (US) 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130190296-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION TRPC4, TRPC3, TRPC1 TRPM8 10/4885TP53 101/4885POLB 4508/4885
US-20120094977-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION TRPC4, TRPC3, TRPC1 TRPM8 8/4885TP53 51/4885POLB 4566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.